|
Gene: PITPNB |
Gene summary for PITPNB |
Gene summary. |
Gene information | Species | Human | Gene symbol | PITPNB | Gene ID | 23760 |
Gene name | phosphatidylinositol transfer protein beta | |
Gene Alias | PI-TP-beta | |
Cytomap | 22q12.1 | |
Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | P48739 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23760 | PITPNB | C57 | Human | Oral cavity | OSCC | 3.11e-03 | 4.00e-01 | 0.1679 |
23760 | PITPNB | C06 | Human | Oral cavity | OSCC | 3.95e-10 | 1.48e+00 | 0.2699 |
23760 | PITPNB | C08 | Human | Oral cavity | OSCC | 9.01e-18 | 5.79e-01 | 0.1919 |
23760 | PITPNB | LN22 | Human | Oral cavity | OSCC | 6.33e-03 | 7.86e-01 | 0.1733 |
23760 | PITPNB | LN46 | Human | Oral cavity | OSCC | 7.82e-04 | 5.17e-01 | 0.1666 |
23760 | PITPNB | LP15 | Human | Oral cavity | LP | 3.65e-04 | 1.06e+00 | 0.2174 |
23760 | PITPNB | EOLP-1 | Human | Oral cavity | EOLP | 1.19e-05 | 2.31e-01 | -0.0202 |
23760 | PITPNB | NEOLP-1 | Human | Oral cavity | NEOLP | 4.25e-05 | 3.69e-01 | -0.0194 |
23760 | PITPNB | NEOLP-3 | Human | Oral cavity | NEOLP | 9.29e-09 | 3.49e-01 | -0.0191 |
23760 | PITPNB | SYSMH1 | Human | Oral cavity | OSCC | 1.32e-04 | 2.51e-01 | 0.1127 |
23760 | PITPNB | SYSMH2 | Human | Oral cavity | OSCC | 5.77e-15 | 6.60e-01 | 0.2326 |
23760 | PITPNB | SYSMH3 | Human | Oral cavity | OSCC | 5.75e-22 | 9.27e-01 | 0.2442 |
23760 | PITPNB | SYSMH4 | Human | Oral cavity | OSCC | 6.96e-05 | 1.57e-03 | 0.1226 |
23760 | PITPNB | SYSMH5 | Human | Oral cavity | OSCC | 1.56e-08 | 4.00e-01 | 0.0647 |
23760 | PITPNB | GSM5252130_BPH340PrGF_Via | Human | Prostate | BPH | 3.68e-02 | 2.34e-01 | -0.1972 |
23760 | PITPNB | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 2.97e-06 | 7.35e-01 | -0.2247 |
23760 | PITPNB | GSM5252133_BPH389PrSF | Human | Prostate | BPH | 1.19e-02 | 7.67e-01 | -0.2027 |
23760 | PITPNB | 047563_1562-all-cells | Human | Prostate | BPH | 2.12e-24 | 1.80e-01 | 0.0791 |
23760 | PITPNB | 048752_1579-all-cells | Human | Prostate | BPH | 3.65e-25 | 5.61e-01 | 0.1008 |
23760 | PITPNB | 052095_1628-all-cells | Human | Prostate | BPH | 4.23e-09 | 3.88e-01 | 0.1032 |
Page: 1 2 3 4 5 6 7 8 9 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0048193 | Colorectum | AD | Golgi vesicle transport | 109/3918 | 296/18723 | 1.80e-10 | 1.68e-08 | 109 |
GO:0006890 | Colorectum | AD | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 27/3918 | 52/18723 | 7.67e-07 | 2.70e-05 | 27 |
GO:0010876 | Colorectum | AD | lipid localization | 120/3918 | 448/18723 | 1.59e-03 | 1.33e-02 | 120 |
GO:0006869 | Colorectum | AD | lipid transport | 108/3918 | 398/18723 | 1.67e-03 | 1.39e-02 | 108 |
GO:0015748 | Colorectum | AD | organophosphate ester transport | 42/3918 | 140/18723 | 7.04e-03 | 4.31e-02 | 42 |
GO:00481931 | Colorectum | SER | Golgi vesicle transport | 79/2897 | 296/18723 | 4.20e-07 | 2.15e-05 | 79 |
GO:00068901 | Colorectum | SER | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 20/2897 | 52/18723 | 4.80e-05 | 1.18e-03 | 20 |
GO:00481932 | Colorectum | MSS | Golgi vesicle transport | 101/3467 | 296/18723 | 9.09e-11 | 9.77e-09 | 101 |
GO:00068902 | Colorectum | MSS | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 26/3467 | 52/18723 | 2.66e-07 | 1.10e-05 | 26 |
GO:00108761 | Colorectum | MSS | lipid localization | 104/3467 | 448/18723 | 6.76e-03 | 4.38e-02 | 104 |
GO:00481934 | Colorectum | FAP | Golgi vesicle transport | 77/2622 | 296/18723 | 2.86e-08 | 2.62e-06 | 77 |
GO:00068904 | Colorectum | FAP | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 18/2622 | 52/18723 | 1.48e-04 | 2.29e-03 | 18 |
GO:00068691 | Colorectum | FAP | lipid transport | 81/2622 | 398/18723 | 2.84e-04 | 3.76e-03 | 81 |
GO:00108762 | Colorectum | FAP | lipid localization | 85/2622 | 448/18723 | 1.92e-03 | 1.63e-02 | 85 |
GO:0015914 | Colorectum | FAP | phospholipid transport | 23/2622 | 96/18723 | 6.09e-03 | 3.82e-02 | 23 |
GO:00481935 | Colorectum | CRC | Golgi vesicle transport | 59/2078 | 296/18723 | 5.47e-06 | 2.17e-04 | 59 |
GO:00068692 | Colorectum | CRC | lipid transport | 63/2078 | 398/18723 | 2.36e-03 | 2.26e-02 | 63 |
GO:00108763 | Colorectum | CRC | lipid localization | 68/2078 | 448/18723 | 4.60e-03 | 3.58e-02 | 68 |
GO:004819317 | Esophagus | HGIN | Golgi vesicle transport | 83/2587 | 296/18723 | 8.59e-11 | 8.89e-09 | 83 |
GO:000689016 | Esophagus | HGIN | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 19/2587 | 52/18723 | 3.44e-05 | 8.67e-04 | 19 |
Page: 1 2 3 4 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PITPNB | SNV | Missense_Mutation | c.15G>C | p.Leu5Phe | p.L5F | P48739 | protein_coding | deleterious(0.03) | benign(0.073) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD | |
PITPNB | SNV | Missense_Mutation | c.103N>C | p.Glu35Gln | p.E35Q | P48739 | protein_coding | deleterious(0.04) | probably_damaging(0.975) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
PITPNB | SNV | Missense_Mutation | novel | c.316A>C | p.Lys106Gln | p.K106Q | P48739 | protein_coding | tolerated(0.06) | possibly_damaging(0.675) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PITPNB | SNV | Missense_Mutation | novel | c.140N>G | p.Asn47Ser | p.N47S | P48739 | protein_coding | deleterious(0.01) | possibly_damaging(0.452) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PITPNB | SNV | Missense_Mutation | novel | c.340N>A | p.Glu114Lys | p.E114K | P48739 | protein_coding | deleterious(0.04) | possibly_damaging(0.459) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PITPNB | SNV | Missense_Mutation | c.220N>T | p.Val74Leu | p.V74L | P48739 | protein_coding | tolerated(0.37) | benign(0.007) | TCGA-EI-7002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | irinotecan+5-fluorouracilim | SD | |
PITPNB | SNV | Missense_Mutation | novel | c.662G>A | p.Arg221Gln | p.R221Q | P48739 | protein_coding | tolerated(0.05) | probably_damaging(0.99) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PITPNB | SNV | Missense_Mutation | c.631N>A | p.Val211Ile | p.V211I | P48739 | protein_coding | tolerated(0.56) | benign(0.065) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PITPNB | SNV | Missense_Mutation | c.557G>A | p.Ser186Asn | p.S186N | P48739 | protein_coding | tolerated(1) | benign(0) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
PITPNB | SNV | Missense_Mutation | novel | c.386N>A | p.Gly129Asp | p.G129D | P48739 | protein_coding | tolerated(0.23) | benign(0) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |